Cooperative Agreement UG3CA305780
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Pennsylvania, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $1,684,165 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to Kaiser Foundation Hospitals. The project, titled "Expanding Lung Cancer Screening to Achieve Excellence (EXHALE)", aims to develop and evaluate implementation strategies to increase guideline-concordant lung cancer screening in Federally Qualified Health Centers (FQHCs). The project will form a partnership between 7 FQHC...
- This Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to facilitate the scale-up and sustainment of high-quality lung cancer screening using the QUILS system. The $1,549,462 award, effective September 8, 2025 through August 31, 2027, supports the evaluation of the QUILS system 2.0 in 60 lung cancer screening programs to improve implementation and achieve higher screening rates. The...
- This federal Cooperative Agreement award is from the National Cancer Institute (NCI), under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353). The $1,594,797 award supports a project to evaluate strategies for scaling up and sustaining tobacco use treatment (TUT) in cancer survivors across a network of 72 clinics. The project aims to adapt and refine implementation strategies, harmonize outcome measures, and establish the feasibility of a multi-stage...
- This federal Project Grant award of $429,399 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund research to "RECALIBRATE THE LUNG CANCER POLICY MODEL (LCPM) TO ADDRESS LUNG CANCER RISK AND LUNG CANCER SCREENING PRACTICES IN REAL-WORLD POPULATIONS." The goal is to improve the LCPM's accuracy in estimating the health and economic impacts of low-dose computed tomography (LDCT) lung cancer screening by 1) adjusting the model to reflect...
- The U.S. National Cancer Institute (NCI) awarded a $158,290 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Kaiser Foundation Hospitals to conduct a study on "Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems." This 2-year project, running from July 2024 to July 2026, aims to produce estimates of overdiagnosis among patients diagnosed with lung cancer who participated in lung cancer...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $968,999 to the University of North Carolina at Chapel Hill to conduct a research study titled "OPTIMIZING SURVEILLANCE IN LUNG CANCER SURVIVORS WITH NOVEL IMAGING BIOMARKERS AND DEEP-LEARNING (OPTIMAL)". The goal of the study is to optimize post-treatment surveillance and monitoring of early-stage non-small cell lung cancer survivors by leveraging routine...
- This Project Grant award of $1,131,820.00 from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports research to characterize toxicities and health-related quality of life outcomes among a diverse sample of 416 individuals receiving immune checkpoint inhibitor treatment for metastatic cancer. The study aims to examine associations between patient sociodemographic/medical factors and symptomatic toxicities and quality of...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh. The grant will fund a "Hybrid Type I Cluster Randomized Effectiveness-Implementation Trial of CARES" to address clinically significant levels of depression, pain, and fatigue experienced by over 18 million Americans living with cancer. The project aims to...
- This federal Project Grant award of $166,800.00 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research at Pennsylvania State University's Milton S. Hershey Medical Center to investigate a novel combination therapy approach for an aggressive subtype of lung adenocarcinoma. The research aims to characterize how the loss of the MTSS1 protein impacts the tumor immune microenvironment in SMARCA4-mutant lung adenocarcinoma, and evaluate the...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $566,523 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to identify interception targets in persistent lung premalignant lesions (PMls) that are at risk of progressing to lung cancer. The key objectives are to: 1) Identify interception targets in the persistence profile in clinical trial biopsies, 2) Determine effects of...